PUPs A-LONG 试验中未治疗的重型A型血友病患者抑制物发生的回顾性分析
本文为3期PUPs A-LONG试验的事后分析,纳入6岁以下未治疗的男性重型A型血友病患者,接受rFVIIIFc治疗,抑制物发生为主要终点。分析显示高危F8变异与高滴度抑制物发生相关(P = .028),低滴度抑制物进展为高滴度者的每次输注平均剂量(98.4 IU/kg,n = 5)高于自发消退者(59.2 IU/kg,n = 7;P = .033)或持续存在者(45.0 IU/kg,n = 5;P = .047)。中心静脉置管手术与抑制物发生无关联。
要点
- 高危F8变异与高滴度抑制物发生相关(P = .028)。
- 低滴度抑制物进展为高滴度者的每次输注平均剂量高于自发消退或持续存在者。
- 中心静脉置管手术与抑制物发生无关联。
核心结论
- 事后分析提示F8基因型和因子剂量是与抑制物风险同等重要的因素,需进一步研究。
研究设计与样本
- PUPs A-LONG为3期研究,纳入6岁以下未治疗的男性重型A型血友病患者,接受rFVIIIFc治疗,抑制物发生为主要终点。
- 本分析为事后分析,包括治疗方案的描述性分析和Kaplan-Meier分析,以及抑制物发生的特征分析。
主要发现
- 抑制物阳性和阴性患者在年龄、种族和民族方面的基线特征分布相似(所有P > .05)。
- 高危F8变异与高滴度抑制物发生相关(P = .028)。
- 低滴度抑制物进展为高滴度者的每次输注平均剂量(98.4 IU/kg,n = 5)高于自发消退者(59.2 IU/kg,n = 7;P = .033)或持续存在者(45.0 IU/kg,n = 5;P = .047)。
- 中心静脉置管手术与抑制物发生无关联。
局限性
- 事后分析提示F8基因型和因子剂量是与抑制物风险同等重要的因素,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhibitor development is a major therapeutic complication for people with hemophilia. The phase 3 PUPs A-LONG study evaluated the safety and efficacy of efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, herein referred to as rFVIIIFc) in previously untreated patients (PUPs) with severe hemophilia A. Male PUPs <6 years old were enrolled and received rFVIIIFc; inhibitor development was the primary end point. Post hoc analyses, including patient treatment regimen patterns and timing of inhibitor development, descriptive and Kaplan-Meier analyses of time to first inhibitor-positive test by treatment regimen and by titer, and consumption, were performed to describe patients who developed inhibitors during PUPs A-LONG. We investigated patient characteristics (eg, demographics and genotype) and nongenetic risk factors (eg, intense factor exposure and central venous access device [CVAD] placement) that may predict inhibitor development and characteristics of inhibitor development (low-titer vs high-titer inhibitor). Baseline characteristics were similarly distributed for age, race, and ethnicity across both patients who were inhibitor-positive and those who were inhibitor-negative (all P > .05). High-risk F8 variants were associated with development of high-titer inhibitors (P = .028). High-titer inhibitor development was often preceded by the presence of a low-titer inhibitor. Patients whose low-titer inhibitor progressed to a high-titer inhibitor received a higher mean dose per infusion (98.4 IU/kg, n = 5) compared with those whose low-titer inhibitor resolved spontaneously (59.2 IU/kg, n = 7; P = .033) or persisted (45.0 IU/kg, n = 5; P = .047). There was no association between CVAD placement surgery and inhibitor development. Post hoc analyses suggest that F8 genotype and dose of factor are as important as inhibitor risk factors and require further investigation. This study was registered at ClinicalTrials.gov as #NCT02234323.
引用
- Carcao M, Schiavulli M, Kulkarni R, et al. A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial. Blood Adv. 2024. PMID: 38266154. doi:10.1182/bloodadvances.2023011475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。